Vakkalagadda, C., Lee, B., Alex, J., Rakshe, S., Minnier, J., Cetnar, J. P. (2025). Utilizing TP53 mutation status and initial disease burden at presentation to risk-stratify patients with advanced EGFR-mutated NSCLC treated with osimertinib.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e20663